Accure Therapeutics

Accure Therapeutics is a Barcelona-based neuroscience R&D company developing ACT-02, a novel drug candidate with disease-modifying potential for Parkinson's disease. ACT-02 inhibits Prolyl Endopeptidase (PREP), a promising target in Parkinson's. The company is currently in an advanced preclinical stage.


Buy Funded Startups lists

Funding Round: Grant

Funding Amount: €1.46M

Date: 07-Apr-2025

Investors: The Michael J. Fox Foundation, Luxembourg National Research Fund (FNR)

Markets: Biotechnology, Neuroscience, Pharmaceuticals, HealthTech, Life Sciences

HQ: Barcelona, Catalonia, Spain

Founded: 2020

Website: https://accure.health/

LinkedIn: https://www.linkedin.com/company/accure-therapeutics

Twitter: https://twitter.com/AccureTherapeut

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/accure-therapeutics

Pitchbook: https://pitchbook.com/profiles/company/435462-49


Leave a Comment